Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Br J Pharmacol ; 171(12): 3103-14, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24611770

ABSTRACT

BACKGROUND AND PURPOSE: We determined the effects of treatment with LR-90, an inhibitor of advanced glycation end products, on the mechanical properties of the arterial system in streptozotocin (STZ)-induced diabetic Sprague Dawley rats, using aortic impedance analysis, and further investigated the effects of LR-90 on the progression of aortic pathology. EXPERIMENTAL APPROACH: STZ-induced diabetic rats were treated with or without LR-90 (50 mg L(-1) in drinking water) for 8 weeks and compared with control groups. Arterial BP measurements, various metabolic parameters, aortic histopathology, collagen cross-linking, AGE accumulation, and RAGE protein expression in aortic tissue were determined. Pulsatile parameters were evaluated using a standard Fourier series expansion technique and impulse response function of the filtered aortic input impedance spectra. KEY RESULTS: LR-90 reduced glycated haemoglobin and triglycerides levels, although it had no effect on the glycaemic status. LR-90 did not affect arterial BP, but prevented the diabetes-induced increase in peripheral resistance and variations in aortic distensibility, as it reduced aortic characteristic impedance by 21%. LR-90 also prevented the elevation in wave reflection factor, as indicated by a 22.5% reduction and an associated increase of 23.5% in wave transit time, suggesting it prevents the augmentation of the systolic load of the left ventricle. Moreover, LR-90 inhibited collagen cross-linking and the accumulation of AGE and RAGE in the vasculature of diabetic rats. CONCLUSIONS AND IMPLICATIONS: Treatment with LR-90 may impart significant protection against diabetes-induced aortic stiffening and cardiac hypertrophy and provides an additional therapeutic option for treatment of AGE associated diabetic complications.


Subject(s)
Aorta/drug effects , Butyrates/pharmacology , Diabetes Mellitus, Experimental/drug therapy , Diabetic Angiopathies/prevention & control , Glycation End Products, Advanced/antagonists & inhibitors , Hypoglycemic Agents/pharmacology , Vascular Stiffness/drug effects , Animals , Aorta/metabolism , Aorta/pathology , Aorta/physiopathology , Blood Pressure/drug effects , Cardiomegaly/blood , Cardiomegaly/physiopathology , Cardiomegaly/prevention & control , Collagen/metabolism , Compliance , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/pathology , Diabetes Mellitus, Experimental/physiopathology , Diabetic Angiopathies/blood , Diabetic Angiopathies/pathology , Diabetic Angiopathies/physiopathology , Glycated Hemoglobin/metabolism , Glycation End Products, Advanced/metabolism , Male , Rats, Sprague-Dawley , Receptor for Advanced Glycation End Products , Receptors, Immunologic/drug effects , Receptors, Immunologic/metabolism , Time Factors , Triglycerides/blood , Vascular Resistance/drug effects
2.
Diabetologia ; 51(5): 882-91, 2008 May.
Article in English | MEDLINE | ID: mdl-18317729

ABSTRACT

AIMS/HYPOTHESIS: Previous studies have shown that LR-90, a new inhibitor of AGE formation, prevented the development of experimental type 1 diabetic nephropathy. In this study, we examined the effects of LR-90 in the Zucker diabetic fatty (ZDF) rat, a model of type 2 diabetes and metabolic syndrome, and investigated the mechanisms by which it may protect against renal injury. METHODS: Male ZDF rats were treated without or with LR-90 from age 13 to 40 weeks. Metabolic and kidney functions and renal histology were evaluated. AGE accumulation and the production of the receptor for AGE (AGER) were measured. Profibrotic growth factors, extracellular matrix proteins and intracellular signalling pathways associated with glomerular and tubular damage were also analysed. RESULTS: LR-90 dramatically reduced plasma lipids in ZDF rats, with only modest effects on hyperglycaemia. Renal AGE, AGER and lipid peroxidation were all attenuated by LR-90. LR-90 significantly retarded the increase in albuminuria and proteinuria. This was associated with reduction in glomerulosclerosis and tubulointerstitial fibrosis, concomitant with marked inhibition of renal overproduction of TGF-beta1, connective tissue growth factor, fibronectin and collagen IV. Additionally, LR-90 downregulated the activation of key mitogen-activated protein kinases (MAPKs) and nuclear factor kappa B (NF-kappaB) in the renal cortex. CONCLUSIONS/INTERPRETATION: These results support our earlier studies on the renoprotective effects of LR-90 on type 1 diabetic nephropathy and provide further evidence that LR-90, an AGE inhibitor with pleiotrophic effects, may also be beneficial for the prevention of type 2 diabetic nephropathy, where multiple risk factors, such as hyperglycaemia, dyslipidaemia, obesity, insulin resistance and hypertension, contribute to renal injury.


Subject(s)
Butyrates/therapeutic use , Diabetic Nephropathies/prevention & control , Dyslipidemias/prevention & control , Animals , Blood Glucose/drug effects , Blood Glucose/metabolism , Blood Pressure , Diabetes Mellitus, Type 2/prevention & control , Diabetic Nephropathies/pathology , Diabetic Nephropathies/physiopathology , Heart Rate , Kidney/pathology , Kidney Function Tests , Rats , Rats, Zucker , Triglycerides/blood
3.
Br J Ophthalmol ; 92(4): 545-7, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18211931

ABSTRACT

BACKGROUND: Diabetic retinopathy is associated with accumulation of advanced glycation end products in the retinal microvasculature. LR-90 is an effective multistage inhibitor of advanced glycation with renoprotective and anti-inflammatory properties. AIM: To explore the role of LR-90 in the progression of experimental diabetic retinopathy. METHODS: Streptozotocin-induced diabetic Sprague-Dawley rats were treated with LR-90 (50 mg/l in drinking water) for up to 32 weeks. At the end of the study, eyes were enucleated and subjected to trypsin digestion and staining with light green/haematoxylin. Acellular capillaries and pericytes were quantified in random fields using light microscopy. RESULTS: In the LR-90-treated diabetic animals, acellular capillary numbers were reduced to 1.63 (0.20) from 2.58 (0.49) (p<0.05) in diabetic controls. LR-90 treatment also restored the pericyte deficit from 18.12 (0.98) in diabetic rats to 24.19 (0.76) (p<0.001). CONCLUSION: These findings show that LR-90 can effectively inhibit important lesions of diabetic retinopathy. This agent has potential for preventing retinopathy in patients with diabetes.


Subject(s)
Butyrates/therapeutic use , Diabetic Retinopathy/prevention & control , Glycation End Products, Advanced/antagonists & inhibitors , Animals , Body Weight/drug effects , Cholesterol/blood , Creatinine/urine , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Experimental/pathology , Diabetic Retinopathy/pathology , Disease Progression , Drug Evaluation, Preclinical/methods , Male , Rats , Rats, Sprague-Dawley , Triglycerides/blood
4.
Diabetologia ; 46(8): 1140-52, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12845431

ABSTRACT

AIMS/HYPOTHESIS: Advanced glycation and lipoxidation endproducts have been implicated in the pathogenesis of diabetic complications, including diabetic nephropathy. LR-90, a new advanced glycation endproduct inhibitor, was investigated for its effects on the development of renal disease in diabetic rats. METHODS: Diabetic animals were randomly allocated into groups receiving LR-90 or vehicle (untreated). Age- and weight-matched non-diabetic rats were studied concurrently. Body weight, plasma glucose, glycated haemoglobin, urinary albumin and creatine excretions were measured serially. Kidney histopathology, AGE accumulation in cells and tissues, protein oxidation, were also examined. In vitro assays were used to assess the possible mechanism of action of LR-90. RESULTS: LR-90 inhibited the increase in albumin and creatinine concentrations, and concentrations of circulating AGE in diabetic rats without any effect on glycaemic control. LR-90 treated-rats also showed higher body weights than untreated diabetic rats. LR-90 prevented glomerulosclerosis, tubular degeneration and collagen deposition in the kidney. AGE-induced cross-linking and fluorescence of tail collagen were reduced by LR-90 treatment. LR-90 also decreased AGE accumulation in kidney glomeruli and nitrotyrosine deposition in the renal cortex. In vitro, LR-90 was capable of reacting with reactive carbonyl compounds and was a more potent metal chelator than pyridoxamine and aminoguanidine. CONCLUSION/INTERPRETATION: LR-90 reduces in vivo AGE accumulation, AGE-protein cross-linking and protein oxidation, and could be beneficial in preventing the progression of diabetic nephropathy. The AGE inhibitory and therapeutic effects of LR-90 could be attributed, at least in part, to its ability to react with reactive carbonyl species and/or potent metal chelating activity that inhibits glycoxidative-AGE formation.


Subject(s)
Butyrates/therapeutic use , Diabetes Mellitus, Experimental/physiopathology , Diabetic Nephropathies/prevention & control , Glycation End Products, Advanced/antagonists & inhibitors , Animals , Blood Glucose/metabolism , Body Weight , Glycated Hemoglobin/analysis , Kidney/pathology , Kidney Function Tests , Male , Rats , Rats, Sprague-Dawley , Reference Values
5.
Vet Parasitol ; 102(4): 341-54, 2001 Dec 28.
Article in English | MEDLINE | ID: mdl-11731077

ABSTRACT

Myiasis caused by screwworms, Cochliomyia hominivorax (Coquerel), is devastating to warm-blooded animals and economically important to livestock producers. It is difficult to distinguish these pests, immature screwworms, from immatures of other non-pest fly species that often occur in animal wounds; it would be helpful to have tools available that do not rely on morphological characteristics. We developed two monoclonal antibodies (MAbs), highly specific for the screwworm, and used them in an enzyme-linked immunosorbent assay (MAb-ELISA), that differentiated screwworm eggs, larvae, pupae, and adults from those of the closely related secondary screwworm, C. macellaria (Fabricius) as well as Phormia regina (Meigen), Phaenicia sericata (Meigen), Calliphora vicina Robineau-Desvoidy, and Chrysomya rufifacies (Macquart). In a blind study, the microplate MAb-ELISA, which took about 4h to complete, displayed high specificity (99%), sensitivity (92%) and overall accuracy (97%) in distinguishing all life stages of the screwworm. Electrophoresis results suggested that the two monoclonal antibodies recognized identical conformational epitopes present in all screwworm life stages. The screwworm eradication program, successful in eradicating this pest from the US, Mexico, most of Central America and Libya (after an accidental introduction), could benefit in future eradication, surveillance, and exclusion efforts by developing a reliable field identification kit based on MAb-ELISA that accurately and quickly distinguished cases of screwworm myiasis.


Subject(s)
Antibodies, Monoclonal , Diptera/immunology , Enzyme-Linked Immunosorbent Assay/veterinary , Screw Worm Infection/veterinary , Animals , Diagnosis, Differential , Diptera/growth & development , Enzyme-Linked Immunosorbent Assay/methods , Female , Mice , Mice, Inbred BALB C , Parasite Egg Count/veterinary , Pupa , Random Allocation , Reproducibility of Results , Screw Worm Infection/diagnosis , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...